$62.8 Million is the total value of Foresite Capital Management III, LLC's 9 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 70.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MYOK | Buy | Myokardia, Inc. | $18,070,000 | -24.1% | 385,452 | +18.1% | 28.77% | +115.8% |
| EPZM | Buy | Epizyme, Inc. | $11,071,000 | -34.5% | 713,812 | +3.8% | 17.63% | +86.0% |
| BPMC | New | Blueprint Medicines Corporation | $9,936,000 | – | 169,900 | +100.0% | 15.82% | – |
| NTRA | Natera, Inc. | $6,234,000 | -11.4% | 208,768 | 0.0% | 9.93% | +151.9% | |
| IMMU | Sell | Immunomedics, Inc. | $5,392,000 | -85.4% | 400,000 | -77.1% | 8.59% | -58.6% |
| AERI | Sell | Aerie Pharmaceuticals, Inc. | $4,813,000 | -91.5% | 356,492 | -84.8% | 7.66% | -75.9% |
| XLRN | Sell | Acceleron Pharma Inc. | $3,777,000 | -72.1% | 42,030 | -83.5% | 6.01% | -20.6% |
| BHVN | New | Biohaven Pharmaceutical Holding Company Ltd. | $2,118,000 | – | 62,245 | +100.0% | 3.37% | – |
| FGEN | New | FibroGen, Inc. | $1,390,000 | – | 40,000 | +100.0% | 2.21% | – |
| ASND | Exit | Ascendis Pharma A/Ssponsored adr | $0 | – | -13,922 | -100.0% | -1.09% | – |
| CBAY | Exit | CymaBay Therapeutics, Inc. | $0 | – | -1,504,710 | -100.0% | -1.65% | – |
| REPL | Exit | Replimune Group, Inc. | $0 | – | -313,922 | -100.0% | -2.52% | – |
| BOLD | Exit | Audentes Therapeutics, Inc. | $0 | – | -233,067 | -100.0% | -7.82% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 24 | Q3 2021 | 17.6% |
| Acceleron Pharma Inc. | 22 | Q3 2021 | 25.9% |
| CymaBay Therapeutics, Inc. | 20 | Q3 2022 | 17.6% |
| Aerie Pharmaceuticals, Inc. | 18 | Q1 2020 | 33.5% |
| Ascendis Pharma A/S | 17 | Q3 2022 | 47.8% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 27.4% |
| Natera, Inc. | 16 | Q3 2022 | 21.5% |
| Aimmune Therapeutics, Inc. | 16 | Q3 2019 | 8.1% |
| Verona Pharma PLC. | 15 | Q3 2022 | 30.0% |
| WAVE Life Sciences Ltd. | 15 | Q2 2019 | 20.0% |
View Foresite Capital Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 4 | 2021-11-03 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 3 | 2021-02-10 |
View Foresite Capital Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.